Apr 23, 2021 by Jia Jie ChenWith Important Trial Results Due in June, Is This Drugmaker a Good Buy Now?The company faced challenges last year in expanding the label of its only drug. Will 2021 bring different results?
Apr 21, 2021 by Jia Jie Chen1 Drug, 1 Mission: What Should Investors Expect for Greenwich Life Sciences?The top-performing IPO of 2020 is a high-risk, high-reward opportunity, with one drug in its pipeline and one disease in its sights. Is it worth investing in now?
Apr 16, 2021 by Jia Jie ChenAre Disappointing Results an Opportunity for Frequency Therapeutics Investors?A risky path lies ahead for the clinical-stage biotech, which saw disappointing results for FX-322 in March 2021. Can management learn from its mistakes?
Apr 12, 2021 by Jia Jie ChenWith a New Diabetes Product Coming to Market, What Lies Ahead for Zealand Pharma Investors?A new, easier-to-administer treatment for severe hypoglycemia has observers and investors wondering where its creators will go next.
Apr 7, 2021 by Jia Jie ChenAn End to This Rare Syndrome Could Be an Opportunity for InvestorsA rare genetic disease that causes combined blindness and deafness may have a novel treatment in line after positive phase 1/2 trial results last month.
Apr 1, 2021 by Jia Jie ChenIs Sarepta Therapeutics Worthy of Redemption?A potentially misinterpreted clinical trial readout from January may mean a market opportunity for bargain hunters.
Mar 26, 2021 by Jia Jie ChenThe Promises Behind Terns' Multi-Pronged PipelineThis pharma may be a newcomer to the stock market, but it has several innovative drugs in development for a common condition with no current treatments approved.
